Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 211 to 220 of 999 total matches.

In Brief: Airborne

   
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005  (Issue 1199)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
Patients may be asking about Airborne, a dietary supplement that is being heavily promoted for prevention and treatment of colds. It contains 7 herbal extracts, 3 vitamins, 2 amino acids, selenium, zinc and many other ingredients. Airborne Jr is available for children. There are some concerns. First, there is no conclusive evidence that this product or any of its ingredients prevents colds or shortens their duration. Second, the adult tablet contains 1 g of vitamin C, and the directions for use advise taking 1 tablet at the first sign of a cold and repeating the dose every 3 hours as...
Med Lett Drugs Ther. 2005 Jan 3;47(1199):4 |  Show IntroductionHide Introduction

In Brief: Adderall

   
The Medical Letter on Drugs and Therapeutics • Mar 28, 2005  (Issue 1205)
R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York University School ...
On February 9, 2005, Health Canada suspended the marketing of Adderall XR (Shire), a mixture of amphetamine salts used to treat attention-deficit hyperactivity disorder (ADHD) (Med Lett Drugs Ther 1994; 36:109). The immediate-release form of Adderall was never marketed in Canada. The withdrawal was based on 20 reports internationally of sudden death in patients taking the drug. These deaths, 14 of them in children, were not linked to overdose or abuse. The FDA decided that the number of sudden deaths was no greater than expected among the large number of people taking the drug, but because 5...
Med Lett Drugs Ther. 2005 Mar 28;47(1205):28 |  Show IntroductionHide Introduction

In Brief: Hypo- and Hyperglycemia with Gatifloxacin (Tequin)

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006  (Issue 1230)
., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D ...
A study now available on the web site of The New England Journal of Medicine (LY Park-Wyllie et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. www.nejm.org, published online March 1, 2006) reports an increased risk of hypoglycemia (RR 4.3) and hyperglycemia (RR 16.7) with use of gatifloxacin (Tequin), a fluoroquinolone antibiotic. The Medical Letter published an article on this risk in 2003 (vol. 45, page 64); at that time the extent to which other fluoroquinolones carried the same risk was unclear. The recent report indicates that, except for a slightly increased...
Med Lett Drugs Ther. 2006 Mar 13;48(1230):24 |  Show IntroductionHide Introduction

In Brief: Telithromycin Hepatotoxicity

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2006  (Issue 1233)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
Telithromycin (Ketek) is an oral erythromycin derivative FDA-approved for treatment of mild to moderate community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial sinusitis (Med Lett Drugs Ther 2004; 46:66). It is generally considered an alternative antibiotic because of its cost, potential for adverse effects including visual disturbances, exacerbation of myasthenia gravis, hepatotoxicity and drug interactions. A recent report (Ann Intern Med 2006; 144:415) described serious hepatotoxicity probably related to telithromycin in three patients, including one who died...
Med Lett Drugs Ther. 2006 Apr 24;48(1233):33 |  Show IntroductionHide Introduction

Correction: Panitumumab Dosage

   
The Medical Letter on Drugs and Therapeutics • Jun 04, 2007  (Issue 1262)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
In the CLINICAL STUDIES - Other Cancers paragraph (Med Lett Drugs Ther 2007; 49:35), the dosage in the first line should be 2.5 mg/kg, not 25 mg/kg.
Med Lett Drugs Ther. 2007 Jun 4;49(1262):48 |  Show IntroductionHide Introduction

Correction: The EarCheck Middle Ear Monitor

   
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008  (Issue 1292)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
The article in the July 14th issue contained an error in the last sentence of the last paragraph beginning on page 55. The instrument's reading is determined not by the degree of protrusion of the tympanic membrane, but rather by its mobility.
Med Lett Drugs Ther. 2008 Aug 11;50(1292):64 |  Show IntroductionHide Introduction

Correction: CT Colonography

   
The Medical Letter on Drugs and Therapeutics • Dec 15, 2008  (Issue 1301)
. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University ...
(Med Lett Drugs Ther 2008; 50:94) In table 1, "Invasive" should be "less" and "more" rather than "no" and "yes" for CT colonography and colonoscopy, respectively.
Med Lett Drugs Ther. 2008 Dec 15;50(1301):97-100 |  Show IntroductionHide Introduction

In Brief: A New Indication for Abemaciclib (Verzenio) (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
robustness is essential for decisionmaking in early breast cancer. Breast 2020; 51:120. 3. R Nishimura et al ...
The oral cyclin-dependent kinase (CDK) 4/6 inhibitor abemaciclib (Verzenio – Lilly) has been approved by the FDA for use in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.1It was previously approved for the same indication, but patients were also required to have a Ki-67 score ≥20%. About 70% of all breast cancers are HR-positive and HER2-negative. Ki-67 is a...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e62-3   doi:10.58347/tml.2023.1673g |  Show IntroductionHide Introduction

NovolinPen for Insulin Injection

   
The Medical Letter on Drugs and Therapeutics • Dec 30, 1988  (Issue 782)
are available: regular insulin (Novolin R PenFill), NPH insulin isophane (Novolin N PenFill) and a mixture of 70 ...
The NovolinPen (Squibb - Novo) is a device that uses prefilled cartridges to inject semisynthetic human insulin (Medical Letter, 25:63, 1983). Three formulations are available: regular insulin (Novolin R PenFill), NPH insulin isophane (Novolin N PenFill) and a mixture of 70% NPH and 30% regular (Novolin 70/30 PenFill). The NovolinPen is advertised as more accurate, more convenient and less expensive than conventional syringes and needles. The same device is marketed in Canada as the Novolin-Pen II (Connaught Novo). (An earlier device is also available as the Novolin-Pen in Canada and the...
Med Lett Drugs Ther. 1988 Dec 30;30(782):117-8 |  Show IntroductionHide Introduction

Desmopressin for Nocturnal Enuresis

   
The Medical Letter on Drugs and Therapeutics • Apr 20, 1990  (Issue 816)
hyponatremia and had a grand mal seizure (MFM Bamford and G Cruickshank, J R Coll Gen Pract, 39:345, 1989 ...
Desmopressin acetate (DDAVP -Rorer), a synthetic analog of the natural human antidiuretic hormone arginine vasopressin, was recently approved by the US Food and Drug Administration for treatment of primary nocturnal enuresis. DDAVP Nasal Spray, which is similar to an intranasal solution that has been available in the USA for treatment of central diabetes insipidus (Medical Letter, 20:26, 1978), will be used for the new indication.
Med Lett Drugs Ther. 1990 Apr 20;32(816):38-9 |  Show IntroductionHide Introduction